Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT04335292
Title Osimertinib Then Chemotherapy in EGFR-mutated Lung Cancer With Osimertinib Third-line Rechallenge (OCELOT)
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors Mark Vincent
Indications

lung non-small cell carcinoma

Therapies

Cisplatin + Pemetrexed Disodium

Carboplatin + Pemetrexed Disodium

Osimertinib

Age Groups: senior | adult
Covered Countries CAN


No variant requirements are available.